RU2013118453A - Катионы одновалентных металлов сухих порошков для ингаляций - Google Patents
Катионы одновалентных металлов сухих порошков для ингаляций Download PDFInfo
- Publication number
- RU2013118453A RU2013118453A RU2013118453/15A RU2013118453A RU2013118453A RU 2013118453 A RU2013118453 A RU 2013118453A RU 2013118453/15 A RU2013118453/15 A RU 2013118453/15A RU 2013118453 A RU2013118453 A RU 2013118453A RU 2013118453 A RU2013118453 A RU 2013118453A
- Authority
- RU
- Russia
- Prior art keywords
- dry powder
- dry
- powder according
- particles
- less
- Prior art date
Links
- 239000000843 powder Substances 0.000 title claims abstract 36
- 229910052751 metal Inorganic materials 0.000 title claims abstract 17
- 239000002184 metal Substances 0.000 title claims abstract 17
- 150000002739 metals Chemical class 0.000 title claims abstract 6
- 239000002245 particle Substances 0.000 claims abstract 34
- 150000001768 cations Chemical class 0.000 claims abstract 16
- 150000003839 salts Chemical class 0.000 claims abstract 12
- 239000013543 active substance Substances 0.000 claims abstract 9
- 238000007561 laser diffraction method Methods 0.000 claims abstract 4
- PZSMUPGANZGPBF-UHFFFAOYSA-N 4-[5-(dithiolan-3-yl)pentanoylamino]butanoic acid Chemical compound OC(=O)CCCNC(=O)CCCCC1CCSS1 PZSMUPGANZGPBF-UHFFFAOYSA-N 0.000 claims abstract 2
- 235000017274 Diospyros sandwicensis Nutrition 0.000 claims abstract 2
- 241000282838 Lama Species 0.000 claims abstract 2
- 229940110339 Long-acting muscarinic antagonist Drugs 0.000 claims abstract 2
- 239000003242 anti bacterial agent Substances 0.000 claims abstract 2
- 230000003115 biocidal effect Effects 0.000 claims abstract 2
- 239000003246 corticosteroid Substances 0.000 claims abstract 2
- 239000010419 fine particle Substances 0.000 claims abstract 2
- 229940125389 long-acting beta agonist Drugs 0.000 claims abstract 2
- 235000002639 sodium chloride Nutrition 0.000 claims 10
- 238000000034 method Methods 0.000 claims 4
- 210000002345 respiratory system Anatomy 0.000 claims 4
- 208000023504 respiratory system disease Diseases 0.000 claims 4
- 239000002775 capsule Substances 0.000 claims 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 230000003434 inspiratory effect Effects 0.000 claims 2
- 159000000000 sodium salts Chemical class 0.000 claims 2
- XFDUHJPVQKIXHO-UHFFFAOYSA-N 3-aminobenzoic acid Chemical group NC1=CC=CC(C(O)=O)=C1 XFDUHJPVQKIXHO-UHFFFAOYSA-N 0.000 claims 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- 241000989747 Maba Species 0.000 claims 1
- 239000005913 Maltodextrin Substances 0.000 claims 1
- 229920002774 Maltodextrin Polymers 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 206010048908 Seasonal allergy Diseases 0.000 claims 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000009267 bronchiectasis Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 230000005713 exacerbation Effects 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 230000004047 hyperresponsiveness Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 229920002521 macromolecule Polymers 0.000 claims 1
- 229940035034 maltodextrin Drugs 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims 1
- 239000000333 selective estrogen receptor modulator Substances 0.000 claims 1
- 229940095743 selective estrogen receptor modulator Drugs 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000001509 sodium citrate Substances 0.000 claims 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 1
- 235000011083 sodium citrates Nutrition 0.000 claims 1
- 239000001540 sodium lactate Substances 0.000 claims 1
- 229940005581 sodium lactate Drugs 0.000 claims 1
- 235000011088 sodium lactate Nutrition 0.000 claims 1
- 229910052938 sodium sulfate Inorganic materials 0.000 claims 1
- 235000011152 sodium sulphate Nutrition 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
Abstract
1. Вдыхаемый сухой порошок, содержащий вдыхаемые сухие частицы, которые включаютa) один или более катионов солей одновалентных металлов; при этом одна или несколько солей катионов одновалентных металлов присутствует в количестве по меньшей мере около 3% от веса сухой частицы иb) фармацевтически активное вещество, причем фармацевтически активное вещество является антибиотиком, LABA, LAMA, кортикостероидом или любой их комбинацией,где вдыхаемые сухие частицы имеют объемный медианный геометрический диаметр (ОМГД) около 10 мкм или менее и соотношение диспергируемости (1 бар/4 бар) менее чем 1,5, как измерено способом лазерной дифракции (РОДОС/HELOS системы), и где вдыхаемые сухие частицы имеют плотность утряски между 0,45 г/сми 1,2 г/см, при условии, что вдыхаемые сухие частицы не содержат двухвалентных катионов металлов в количестве 3% или более от веса данной сухой частицы.2. Вдыхаемый сухой порошок по п.1, отличающийся тем, что при дополнительном условии, вдыхаемые сухие частицы не содержат солей двухвалентных катионов металлов в количестве 5% или более от веса сухой частицы.3. Вдыхаемый сухой порошок по п.1, отличающийся тем, что вдыхаемые сухие частицы имеют объемный медианный геометрический диаметр (ОМГД) около 5,0 мкм или менее.4. Вдыхаемый сухой порошок по п.1, отличающийся тем, что вдыхаемые сухие порошки имеют фракцию тонкодисперсных частиц (ФТЧ) менее 5,6 микрона, по меньшей мере в 45%.5. Вдыхаемый сухой порошок по п.1, отличающийся тем, что вдыхаемый сухой порошок имеет массовый медианный аэродинамический диаметр (МСАД) около 5 микрон или менее.6. Вдыхаемый сухой порошок по п.1, отличающийся тем, что вдыхаемый сухой порошок дополнител�
Claims (20)
1. Вдыхаемый сухой порошок, содержащий вдыхаемые сухие частицы, которые включают
a) один или более катионов солей одновалентных металлов; при этом одна или несколько солей катионов одновалентных металлов присутствует в количестве по меньшей мере около 3% от веса сухой частицы и
b) фармацевтически активное вещество, причем фармацевтически активное вещество является антибиотиком, LABA, LAMA, кортикостероидом или любой их комбинацией,
где вдыхаемые сухие частицы имеют объемный медианный геометрический диаметр (ОМГД) около 10 мкм или менее и соотношение диспергируемости (1 бар/4 бар) менее чем 1,5, как измерено способом лазерной дифракции (РОДОС/HELOS системы), и где вдыхаемые сухие частицы имеют плотность утряски между 0,45 г/см3 и 1,2 г/см3, при условии, что вдыхаемые сухие частицы не содержат двухвалентных катионов металлов в количестве 3% или более от веса данной сухой частицы.
2. Вдыхаемый сухой порошок по п.1, отличающийся тем, что при дополнительном условии, вдыхаемые сухие частицы не содержат солей двухвалентных катионов металлов в количестве 5% или более от веса сухой частицы.
3. Вдыхаемый сухой порошок по п.1, отличающийся тем, что вдыхаемые сухие частицы имеют объемный медианный геометрический диаметр (ОМГД) около 5,0 мкм или менее.
4. Вдыхаемый сухой порошок по п.1, отличающийся тем, что вдыхаемые сухие порошки имеют фракцию тонкодисперсных частиц (ФТЧ) менее 5,6 микрона, по меньшей мере в 45%.
5. Вдыхаемый сухой порошок по п.1, отличающийся тем, что вдыхаемый сухой порошок имеет массовый медианный аэродинамический диаметр (МСАД) около 5 микрон или менее.
6. Вдыхаемый сухой порошок по п.1, отличающийся тем, что вдыхаемый сухой порошок дополнительно содержит по меньшей мере один фармацевтически приемлемый наполнитель.
7. Вдыхаемый сухой порошок по п.6, отличающийся тем, что по меньшей мере один наполнитель выбран из группы, состоящей из лейцина, мальтодекстрина, маннита и их комбинаций.
8. Вдыхаемый сухой порошок по п.1, отличающийся тем, что соль одновалентных катионов металлов является солью натрия.
9. Вдыхаемый сухой порошок по п.8, отличающийся тем, что соль натрия является хлоридом натрия, лактатом натрия, цитратом натрия, сульфатом натрия или их комбинацией.
10. Вдыхаемый сухой порошок по п.1, отличающийся тем, что соль одновалентных катионов металлов является солью калия.
11. Вдыхаемый сухой порошок по п.1, отличающийся тем, что плотность утряски порошка более чем 0,55 г/см3.
12. Вдыхаемый сухой порошок по п.1, где вдыхаемые сухие частицы дополнительно характеризуются массой порошка, испускаемой капсулой (СЕРМ) по меньшей мере 80% при испускании из пассивного ингалятора сухого порошка при следующих условиях: общая энергия вдоха менее чем приблизительно 2 Дж при использовании капсулы размера 3, которая заполнена по меньшей мере на 10% вдыхаемыми сухими частицами.
13. Вдыхаемый сухой порошок по п.1, где вдыхаемые сухие частицы дополнительно характеризуются средним диаметром (Dv50) менее чем 5 мкм при испускании из пассивного ингалятора сухого порошка, имеющего сопротивление около 0,036 кПа1/2/л в мин (LPM) при следующих условиях: общая энергия вдоха менее чем приблизительно 1,2 Дж при скорости потока 30 LPM, при использовании капсулы размера 3, которая содержит общую массу 20 мг, где указанная общая масса состоит из вдыхаемых сухих частиц.
14. Вдыхаемый сухой порошок, содержащий вдыхаемые сухие частицы, которые включают
a) один или более катионов солей одновалентных металлов; при этом одна или несколько солей катионов, одновалентных металлов присутствует в количестве по меньшей мере около 3% от веса сухой частицы и
b) фармацевтически активное вещество, причем фармацевтически активное вещество является макромолекулой,
где вдыхаемые сухие частицы имеют объемный медианный геометрический диаметр (ОМГД) около 10 мкм или менее и соотношение диспергируемости (1 бар/4 бар) менее чем 1,5, как измерено способом лазерной дифракции (РОДОС/HELOS системы), и где вдыхаемые сухие частицы имеют плотность утряски между 0,45 г/см3 и 1,2 г/см3, при условии, что вдыхаемые сухие частицы не содержат двухвалентных катионов металлов в количестве 3% или более от веса данной сухой частицы.
15. Вдыхаемый сухой порошок по п.14, отличающийся тем, что фармацевтически активное вещество выбрано из группы, состоящей из антител, гормонов и факторов роста.
16. Способ лечения респираторного заболевания, включающий введение в дыхательные пути пациента, нуждающегося в этом, эффективного количества вдыхаемого сухого порошка по п.1.
17. Способ лечения или профилактики обострения респираторного заболевания, включающий в себя введение в дыхательные пути пациента, нуждающегося в этом, эффективного количество вдыхаемого сухого порошка по п.1.
18. Способ лечения или профилактики инфекционного респираторного заболевания, включающий введение в дыхательные пути пациента, нуждающегося в этом, эффективного количество вдыхаемого сухого порошка по п.1.
19. Способ по п.16, где респираторное заболевание представляет собой астму, гиперреактивность дыхательных путей, сезонную аллергию, бронхоэктатическую болезнь, хронический бронхит, эмфизему, хроническую обструктивную болезнь легких, муковисцидоз.
20. Вдыхаемый сухой порошок, содержащий вдыхаемые сухие частицы, которые включают
a) один или более катионов солей одновалентных металлов; при этом одна или несколько солей катионов одновалентных металлов присутствует, в количестве по меньшей мере около 3% от веса сухой частицы и
b) фармацевтически активное вещество, причем фармацевтически активное вещество представляет собой МАВА,
где вдыхаемые сухие частицы имеют объемный медианный геометрический диаметр (ОМГД) около 10 мкм или менее и соотношение диспергируемости (1 бар/4 бар) менее чем 1,5, измеренное способом лазерной дифракции (РОДОС/HELOS системы), и где вдыхаемые сухие частицы имеют плотность утряски более чем около 0,45 г/см3, при условии, что вдыхаемые сухие частицы не содержат двухвалентных катионов металлов в количестве 3% или более от веса данной сухой частицы.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38788310P | 2010-09-29 | 2010-09-29 | |
US61/387,883 | 2010-09-29 | ||
US201161481879P | 2011-05-03 | 2011-05-03 | |
US61/481,879 | 2011-05-03 | ||
PCT/US2011/053829 WO2012044736A1 (en) | 2010-09-29 | 2011-09-29 | Monovalent metal cation dry powders for inhalation |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2017144619A Division RU2017144619A (ru) | 2010-09-29 | 2011-09-29 | Катионы одновалентных металлов сухих порошков для ингаляций |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2013118453A true RU2013118453A (ru) | 2014-11-10 |
RU2640921C2 RU2640921C2 (ru) | 2018-01-12 |
Family
ID=45002202
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2017144619A RU2017144619A (ru) | 2010-09-29 | 2011-09-29 | Катионы одновалентных металлов сухих порошков для ингаляций |
RU2013118453A RU2640921C2 (ru) | 2010-09-29 | 2011-09-29 | Катионы одновалентных металлов сухих порошков для ингаляций |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2017144619A RU2017144619A (ru) | 2010-09-29 | 2011-09-29 | Катионы одновалентных металлов сухих порошков для ингаляций |
Country Status (12)
Country | Link |
---|---|
US (6) | US9642798B2 (ru) |
EP (2) | EP2621484A1 (ru) |
JP (3) | JP5877204B2 (ru) |
KR (2) | KR20180122475A (ru) |
CN (2) | CN107096014B (ru) |
AU (2) | AU2011308865B2 (ru) |
BR (1) | BR112013007304B1 (ru) |
CA (2) | CA2812414C (ru) |
IL (4) | IL286573B (ru) |
MX (1) | MX354828B (ru) |
RU (2) | RU2017144619A (ru) |
WO (1) | WO2012044736A1 (ru) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2463181B (en) | 2007-05-14 | 2013-03-27 | Univ New York State Res Found | Induction of a physiological dispersion response in bacterial cells in a biofilm |
IL286573B (en) * | 2010-09-29 | 2022-08-01 | Pulmatrix Operating Co Inc | Monovalent metallic cation dry powders for inhalation |
WO2013130767A1 (en) * | 2012-02-29 | 2013-09-06 | Pulmatrix, Inc. | Inhalable dry powders |
US9044035B2 (en) * | 2012-04-17 | 2015-06-02 | R.J. Reynolds Tobacco Company | Remelted ingestible products |
GB201215988D0 (en) * | 2012-09-07 | 2012-10-24 | Reckitt Benckiser Healthcare Int Ltd | Pharmaceutical compositions comprising flurbiprofen |
CN105324106A (zh) * | 2013-04-01 | 2016-02-10 | 普马特里克斯营业公司 | 噻托铵干粉 |
US20170056345A1 (en) * | 2014-02-18 | 2017-03-02 | Stc.Unm | Booster drug therapy for mycobacterium infections |
EP3203985A1 (en) * | 2014-10-08 | 2017-08-16 | Pulmatrix Operating Company, Inc. | Improved stability of dry powders containing tiotropium and amino acid |
US20170304197A1 (en) * | 2014-10-08 | 2017-10-26 | Pulmatrix Operating Company, Inc. | Formulations containing tiotropium, amino acid and acid and methods thereof |
MX2017005692A (es) | 2014-10-31 | 2017-08-07 | Glaxosmithkline Ip Dev Ltd | Formulacion en polvo. |
US10046007B2 (en) | 2015-06-24 | 2018-08-14 | Prescient Pharma, Llc | Compositions and methods for treatment of short telomere disorders |
PT108885B (pt) | 2015-10-12 | 2019-02-13 | Hovione Farm S A | Método de produção de partículas compósitas inaláveis mediante a utilização de um atomizador de três fluidos |
MX2018009159A (es) * | 2016-01-29 | 2019-06-13 | Mannkind Corp | Inhalador de polvo seco. |
CN106116561B (zh) * | 2016-06-28 | 2018-10-12 | 南通众兴磁业有限公司 | 永磁铁氧体磁性材料 |
EA201991096A1 (ru) | 2016-10-31 | 2019-09-30 | Вектура Лимитед | Ингалируемая порошковая композиция, содержащая анти-il-13-антитело |
EP3760189A4 (en) * | 2018-02-26 | 2022-01-05 | Shin Nippon Biomedical Laboratories, Ltd. | PULVERULENT PREPARATION, CARTRIDGE AND DEVICE |
CN110161142A (zh) * | 2019-06-11 | 2019-08-23 | 珠海瑞思普利生物制药有限公司 | 一种表征干粉吸入制剂在呼吸系统空气动力学的仿真装置 |
WO2021012044A1 (en) | 2019-07-22 | 2021-01-28 | Canopy Growth Corporation | Continuous crystallization of cannabinoids in a stirred-tank reactor |
WO2021202429A1 (en) * | 2020-03-28 | 2021-10-07 | Esrail Medical Corp. | Methods and compositions for treatment of covid-19 |
JP2023544638A (ja) * | 2020-10-09 | 2023-10-24 | リウ、チー | 吸入製剤及びその製造方法と使用 |
US20220151920A1 (en) * | 2020-11-18 | 2022-05-19 | Bend Research, Inc. | Inhalable dry powder formulations comprising angiogenesis inhibitors |
WO2024046582A1 (en) * | 2022-09-02 | 2024-03-07 | Liita Care Aps | Pharmaceutical dry powder composition and methods for treating respiratory tract infections |
Family Cites Families (205)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1575050A1 (de) | 1966-01-12 | 1972-04-13 | Misto Gen Equipment Co | Ultraschall-Nebelerzeugungsgeraet |
US4069819A (en) | 1973-04-13 | 1978-01-24 | Societa Farmaceutici S.P.A. | Inhalation device |
US4085893A (en) | 1974-03-20 | 1978-04-25 | Durley Iii Benton A | Ultrasonic humidifiers, atomizers and the like |
US4193009A (en) | 1976-01-26 | 1980-03-11 | Durley Benton A Iii | Ultrasonic piezoelectric transducer using a rubber mounting |
JPS5550437U (ru) | 1978-09-28 | 1980-04-02 | ||
US4233405A (en) | 1979-10-10 | 1980-11-11 | Rohm And Haas Company | Process for spray drying enzymes |
DE3229179C2 (de) | 1982-08-05 | 1986-04-17 | A. Nattermann & Cie GmbH, 5000 Köln | Lungensurfactant |
KR900001873B1 (ko) | 1984-06-14 | 1990-03-26 | 산요덴끼 가부시끼가이샤 | 초음파 가습장치 |
US4637815A (en) | 1985-08-06 | 1987-01-20 | Lemole Gerald M | Irrigational hemostatic solution |
FI82808C (fi) | 1987-12-31 | 1991-04-25 | Etelae Haemeen Keuhkovammayhdi | Ultraljudfinfoerdelningsanordning. |
US5511726A (en) | 1988-09-23 | 1996-04-30 | Battelle Memorial Institute | Nebulizer device |
US4899914A (en) | 1988-11-04 | 1990-02-13 | Ciba-Geigy Corporation | Method for producing a sterile preservative-free aerosol saline solution |
US4921639A (en) | 1988-11-09 | 1990-05-01 | Bernard Chiu | Ultrasonic humidifier |
US4881541A (en) | 1988-12-21 | 1989-11-21 | The Regents Of The University Of California | Vaporizer for an anesthetic having a vapor pressure about one atmosphere |
IT1228459B (it) | 1989-02-23 | 1991-06-19 | Phidea S R L | Inalatore con svuotamento regolare e completo della capsula. |
US5230884A (en) | 1990-09-11 | 1993-07-27 | University Of Wales College Of Cardiff | Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations |
US5175152A (en) | 1990-09-28 | 1992-12-29 | Singh Nikhilesh N | Composition containing ephedrine base and alkyl salicylate for the delivery of ephedrine base in vapor form |
US5211944A (en) | 1990-10-12 | 1993-05-18 | Shaman Pharmaceuticals, Inc. | Proanthocyanidin polymers having antiviral activity and methods of obtaining same |
US5571535A (en) | 1990-11-30 | 1996-11-05 | Flowers; Marianne | Treatment of topical infections |
US5993805A (en) | 1991-04-10 | 1999-11-30 | Quadrant Healthcare (Uk) Limited | Spray-dried microparticles and their use as therapeutic vehicles |
ES2284226T3 (es) | 1991-07-02 | 2007-11-01 | Nektar Therapeutics | Dispositivo para proporcionar medicamentos en aerosol. |
JPH05123398A (ja) | 1991-11-06 | 1993-05-21 | Tsunemasa Kamiyama | 咽喉保護吸入剤並びに吸入器具 |
GB2265845B (en) | 1991-11-12 | 1996-05-01 | Medix Ltd | A nebuliser and nebuliser control system |
US5466680A (en) | 1992-03-26 | 1995-11-14 | Cytologics, Inc. | Method and compositions for enhancing white blood cell functioning on a mucosal or cutaneous surface |
JP3961029B2 (ja) | 1992-06-24 | 2007-08-15 | 博 木戸 | インフルエンザウィルス感染防止剤 |
US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
US5785049A (en) | 1994-09-21 | 1998-07-28 | Inhale Therapeutic Systems | Method and apparatus for dispersion of dry powder medicaments |
US5292127C1 (en) * | 1992-10-02 | 2001-05-22 | Arcade Planet Inc | Arcade game |
US5898037A (en) | 1992-11-13 | 1999-04-27 | Marx; Alvin J. | Formulations of magnesium compounds for local application and methods of treatment using the same |
US5724957A (en) | 1993-01-29 | 1998-03-10 | Aradigm Corporation | Intrapulmonary delivery of narcotics |
US6098620A (en) | 1993-01-29 | 2000-08-08 | Aradigm Corporation | Device for aerosolizing narcotics |
US5709202A (en) | 1993-05-21 | 1998-01-20 | Aradigm Corporation | Intrapulmonary delivery of aerosolized formulations |
NZ328476A (en) | 1993-06-24 | 1999-05-28 | Astra Ab | Use of a two component insulin preparation in an inhalation device |
US5514665A (en) | 1993-12-30 | 1996-05-07 | University Of British Columbia | Method of preventing or reducing the risk of infection by bacterial pathogens utilizing simple and conjugated dextrans |
AUPM411494A0 (en) | 1994-02-25 | 1994-03-24 | Central Sydney Area Health Service | Method and device for the provocation of upper or lower airway narrowing and/or the induction of sputum |
US5633003A (en) | 1994-03-31 | 1997-05-27 | Cantor; Jerome O. | Use of intratracheally administered hyaluronic acid to ameliorate emphysema |
JP3414539B2 (ja) | 1994-05-11 | 2003-06-09 | 有限会社ドット | 経鼻吸収用組成物 |
US6586006B2 (en) | 1994-08-04 | 2003-07-01 | Elan Drug Delivery Limited | Solid delivery systems for controlled release of molecules incorporated therein and methods of making same |
ATE218132T1 (de) | 1994-10-14 | 2002-06-15 | Yamanouchi Pharma Co Ltd | Azol-derivate |
US5863563A (en) | 1994-10-20 | 1999-01-26 | Alphagene Inc. | Treatment of pulmonary conditions associated with insufficient secretion of surfactant |
US5747002A (en) | 1995-04-05 | 1998-05-05 | Genentech, Inc. | Preparation of sodium chloride aerosol formulations |
US5612053A (en) | 1995-04-07 | 1997-03-18 | Edward Mendell Co., Inc. | Controlled release insufflation carrier for medicaments |
US6258341B1 (en) | 1995-04-14 | 2001-07-10 | Inhale Therapeutic Systems, Inc. | Stable glassy state powder formulations |
SK284448B6 (sk) | 1995-04-14 | 2005-04-01 | Glaxo Wellcome Inc. | Merací dávkovací inhalátor |
US6165463A (en) | 1997-10-16 | 2000-12-26 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
JP3708553B2 (ja) | 1995-04-14 | 2005-10-19 | ネクター セラピューティクス | 向上した分散性を有する粉末型薬理組成物 |
US5654007A (en) | 1995-06-07 | 1997-08-05 | Inhale Therapeutic Systems | Methods and system for processing dispersible fine powders |
GB9515182D0 (en) | 1995-07-24 | 1995-09-20 | Co Ordinated Drug Dev | Improvements in and relating to powders for use in dry powder inhalers |
US5628984A (en) | 1995-07-31 | 1997-05-13 | University Of North Carolina At Chapel Hill | Method of detecting lung disease |
US20050054682A1 (en) | 1996-01-04 | 2005-03-10 | Phillips Jeffrey O. | Pharmaceutical compositions comprising substituted benzimidazoles and methods of using same |
GB9606677D0 (en) | 1996-03-29 | 1996-06-05 | Glaxo Wellcome Inc | Process and device |
US6083922A (en) | 1996-04-02 | 2000-07-04 | Pathogenesis, Corp. | Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis |
US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
US6254854B1 (en) | 1996-05-24 | 2001-07-03 | The Penn Research Foundation | Porous particles for deep lung delivery |
US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
USRE37053E1 (en) | 1996-05-24 | 2001-02-13 | Massachusetts Institute Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
RU2140273C1 (ru) * | 1996-11-06 | 1999-10-27 | Закрытое акционерное общество "АЭРОМЕД" | Способ лечения простудных заболеваний |
US6131570A (en) | 1998-06-30 | 2000-10-17 | Aradigm Corporation | Temperature controlling device for aerosol drug delivery |
DE19653969A1 (de) | 1996-12-20 | 1998-06-25 | Boehringer Ingelheim Kg | Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole |
US20030203036A1 (en) * | 2000-03-17 | 2003-10-30 | Gordon Marc S. | Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients |
GB9707934D0 (en) | 1997-04-18 | 1997-06-04 | Danbiosyst Uk | Improved delivery of drugs to mucosal surfaces |
US5881720A (en) | 1997-04-29 | 1999-03-16 | The Procter & Gamble Company | Method of delivering halotherapy |
US20010031244A1 (en) | 1997-06-13 | 2001-10-18 | Chiesi Farmaceutici S.P.A. | Pharmaceutical aerosol composition |
US6339075B1 (en) | 1997-06-30 | 2002-01-15 | The University Of British Columbia | Use of dextran and other polysaccharides to improve mucus clearance |
DE69814428T2 (de) | 1997-09-29 | 2004-05-13 | Nektar Therapeutics, San Carlos | In verneblern verwendbare, stabilisierte zubereitungen |
US6565885B1 (en) | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
GB9807232D0 (en) | 1998-04-03 | 1998-06-03 | Univ Cardiff | Aerosol composition |
CA2327670A1 (en) | 1998-04-08 | 1999-10-14 | Darrel Lavern Allen | Pulmonary and nasal delivery of raloxifene |
US5883084A (en) | 1998-06-08 | 1999-03-16 | Clarion Pharmaceuticals Inc. | Treatment of respiratory diseases utilizing α-tocopheryl-phosphocholine |
SE9802073D0 (sv) | 1998-06-11 | 1998-06-11 | Astra Ab | New use |
WO2000000215A1 (en) | 1998-06-29 | 2000-01-06 | Inhale Therapeutic Systems, Inc. | Particulate delivery systems and methods of use |
FR2780285B1 (fr) | 1998-06-29 | 2001-10-05 | Goemar Lab Sa | Utilisation de solutions salines isoosmotiques, leur procede de preparation et medicaments anti-inflammatoires a base de ces solutions |
GB9814172D0 (en) | 1998-06-30 | 1998-08-26 | Andaris Ltd | Formulation for inhalation |
US6333051B1 (en) | 1998-09-03 | 2001-12-25 | Supratek Pharma, Inc. | Nanogel networks and biological agent compositions thereof |
GB9827145D0 (en) | 1998-12-09 | 1999-02-03 | Co Ordinated Drug Dev | Improvements in or relating to powders |
JP3312216B2 (ja) | 1998-12-18 | 2002-08-05 | オムロン株式会社 | 噴霧装置 |
US6926911B1 (en) | 1998-12-22 | 2005-08-09 | The University Of North Carolina At Chapel Hill | Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs |
ES2228467T3 (es) | 1999-02-03 | 2005-04-16 | Biosante Pharmaceuticals, Inc. | Particulas terapeuticas de fosfato calcico y metodos de fabricacion y su uso. |
EP1173245B1 (en) | 1999-05-03 | 2004-09-01 | Battelle Memorial Institute | Compositions for aerosolization and inhalation |
US6858199B1 (en) | 2000-06-09 | 2005-02-22 | Advanced Inhalation Research, Inc. | High efficient delivery of a large therapeutic mass aerosol |
AU763041B2 (en) * | 1999-08-25 | 2003-07-10 | Alkermes, Inc. | Modulation of release from dry powder formulations |
JP2003507411A (ja) | 1999-08-25 | 2003-02-25 | アドバンスト インハレーション リサーチ,インコーポレイテッド | 噴霧乾燥大多孔性粒子製剤 |
US7678364B2 (en) | 1999-08-25 | 2010-03-16 | Alkermes, Inc. | Particles for inhalation having sustained release properties |
US6749835B1 (en) | 1999-08-25 | 2004-06-15 | Advanced Inhalation Research, Inc. | Formulation for spray-drying large porous particles |
MXPA02004193A (es) | 1999-10-29 | 2002-12-13 | Inhale Therapeutic Syst | Composiciones de polvo seco que tienen caracteristicas de dispersion mejoradas. |
US6962151B1 (en) | 1999-11-05 | 2005-11-08 | Pari GmbH Spezialisten für effektive Inhalation | Inhalation nebulizer |
AU772096B2 (en) | 2000-03-14 | 2004-04-08 | Sumika Enviro-Science Co., Ltd. | Method for denaturing allergens |
SK284948B6 (sk) | 2000-04-06 | 2006-03-02 | Zentiva, A. S. | Liečivý prípravok s obsahom vápnika alebo zmesi vápnika a vitamínu D, alebo zmesi vápnika a horčíka v novej liekovej forme |
GB0008660D0 (en) * | 2000-04-07 | 2000-05-31 | Arakis Ltd | The treatment of respiratory diseases |
PE20011227A1 (es) | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
US6637432B2 (en) | 2000-05-09 | 2003-10-28 | Iep Pharmaceutical Devices Inc. | Inhalation actuated device |
US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
TWI290473B (en) | 2000-05-10 | 2007-12-01 | Alliance Pharma | Phospholipid-based powders for drug delivery |
WO2002000197A1 (en) | 2000-06-27 | 2002-01-03 | Vectura Limited | Method of making particles for use in a pharmaceutical composition |
US7575761B2 (en) | 2000-06-30 | 2009-08-18 | Novartis Pharma Ag | Spray drying process control of drying kinetics |
US6669959B1 (en) | 2000-07-18 | 2003-12-30 | Aeropharm Technology Incorporated | Modulated release particles for lung delivery |
AU2001278131A1 (en) | 2000-08-01 | 2002-02-13 | Shofner Engineering Associates, Inc. | Generation, delivery, measurement and control of aerosol boli for diagnostics and treatments of the respiratory/pulmonary tract of a patient |
US6613308B2 (en) | 2000-09-19 | 2003-09-02 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
WO2002024116A1 (en) | 2000-09-20 | 2002-03-28 | Shahinian, Lee, Jr. | Self-preserved nasal, inhalable, and topical ophthalmic preparations and medications |
US20040081627A1 (en) | 2000-10-09 | 2004-04-29 | Jinks Phillip A | Medicinal aerosol formulations |
PT1920763E (pt) | 2000-11-30 | 2014-06-25 | Vectura Ltd | Composições farmacêuticas para inalação |
CA2432319A1 (en) | 2000-12-21 | 2002-07-18 | Nektar Therapeutics | Pulmonary delivery of polyene antifungal agents |
ES2406405T3 (es) | 2000-12-27 | 2013-06-06 | Gilead Sciences, Inc. | Aztreonam inhalable sin arginina para tratamiento y prevención de infecciones bacterianas pulmonares |
US20020141946A1 (en) | 2000-12-29 | 2002-10-03 | Advanced Inhalation Research, Inc. | Particles for inhalation having rapid release properties |
US6546927B2 (en) | 2001-03-13 | 2003-04-15 | Aerogen, Inc. | Methods and apparatus for controlling piezoelectric vibration |
US6550472B2 (en) | 2001-03-16 | 2003-04-22 | Aerogen, Inc. | Devices and methods for nebulizing fluids using flow directors |
US20030022829A1 (en) | 2001-03-30 | 2003-01-30 | Wendy Maury | Novel antiviral activities primate theta defensins and mammalian cathelicidins |
US6766799B2 (en) | 2001-04-16 | 2004-07-27 | Advanced Inhalation Research, Inc. | Inhalation device |
US6667344B2 (en) | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
US6511050B2 (en) | 2001-05-02 | 2003-01-28 | Dynamo Aviation, Inc. | Humidifier |
US20030138403A1 (en) | 2001-06-29 | 2003-07-24 | Maxygen Aps | Interferon formulations |
JP2003074919A (ja) | 2001-08-31 | 2003-03-12 | Sunbow Precision Co Ltd | 複合式加湿器 |
US20050123509A1 (en) * | 2001-10-19 | 2005-06-09 | Lehrman S. R. | Modulating charge density to produce improvements in the characteristics of spray-dried proteins |
US20030203930A1 (en) | 2001-10-26 | 2003-10-30 | Imtiaz Chaudry | Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease |
AU2002352836B2 (en) | 2001-11-20 | 2005-09-29 | Alkermes, Inc. | Improved particulate compositions for pulmonary delivery |
IL161446A0 (en) | 2001-11-26 | 2004-09-27 | Daiichi Suntory Pharma Co Ltd | Medicinal compositions for nasal absorption |
US6851626B2 (en) | 2002-01-07 | 2005-02-08 | Aerogen, Inc. | Methods and devices for nebulizing fluids |
GB2384198B (en) | 2002-01-18 | 2005-03-02 | Profile Drug Delivery Ltd | Nebulizer metering |
GB0217199D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicament dispenser |
US20030232019A1 (en) | 2002-02-22 | 2003-12-18 | Advanced Inhalation Research, Inc. | Inhalable formulations for sustained release |
PT2630954T (pt) | 2002-03-20 | 2017-01-05 | Civitas Therapeutics Inc | Administração pulmonar de levodopa |
US7008644B2 (en) | 2002-03-20 | 2006-03-07 | Advanced Inhalation Research, Inc. | Method and apparatus for producing dry particles |
GB0207906D0 (en) | 2002-04-05 | 2002-05-15 | 3M Innovative Properties Co | Formoterol and mometasone aerosol formulations |
GB0209782D0 (en) | 2002-04-29 | 2002-06-05 | Glaxo Group Ltd | Medicament dispenser |
US20050220720A1 (en) | 2002-05-02 | 2005-10-06 | David Edwards | Formulations limiting spread of pulmonary infections |
US8003080B2 (en) | 2002-05-13 | 2011-08-23 | Alexza Pharmaceuticals, Inc. | Delivery of drug amines through an inhalation route |
AU2003241477A1 (en) | 2002-06-10 | 2003-12-22 | Elan Pharma International, Ltd. | Nanoparticulate polycosanol formulations and novel polycosanol combinations |
US7405207B2 (en) * | 2002-06-17 | 2008-07-29 | Epigenesis Pharmaceuticals, Inc. | Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof |
PT1531794T (pt) * | 2002-06-28 | 2017-09-14 | Civitas Therapeutics Inc | Epinefrina inalável |
US6916001B2 (en) * | 2002-07-10 | 2005-07-12 | Lowell Thomas Pugh, Jr. | Concrete form apparatus and method for assembly thereof |
GB0217198D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicament dispenser |
US20050271660A1 (en) | 2002-09-06 | 2005-12-08 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
US7112572B2 (en) | 2002-09-09 | 2006-09-26 | Trigen Limited | Multivalent metal salts of boronic acids |
JP2006503865A (ja) | 2002-09-30 | 2006-02-02 | アキュスフィア, インコーポレイテッド | 吸入のための徐放性の多孔性微粒子 |
CN101804200A (zh) | 2002-11-22 | 2010-08-18 | 余芒 | 广谱抗病毒的治疗和预防 |
US7534781B2 (en) | 2003-03-21 | 2009-05-19 | Dsm Ip Assets B.V. | Crystalline amoxicillin trihydrate powder |
CN1194062C (zh) | 2003-04-04 | 2005-03-23 | 王泽斌 | 一种融雪融冰组合物及其制备方法和应用 |
NZ543201A (en) | 2003-05-01 | 2007-05-31 | Innogene Kalbiotech Pte Ltd | Lactate containing pharmaceutical composition and uses thereof |
ATE501766T1 (de) | 2003-05-20 | 2011-04-15 | James F Collins | Ophthalmisches arzneimittelabgabesystem |
US7195179B2 (en) | 2003-06-01 | 2007-03-27 | Piezo Technologies | Piezoelectric mist generation device |
JP2009514779A (ja) | 2003-07-11 | 2009-04-09 | グラクソ グループ リミテッド | 医薬製剤 |
GB0324897D0 (en) | 2003-10-24 | 2003-11-26 | Glaxo Group Ltd | Composition |
GB0324918D0 (en) | 2003-10-24 | 2003-11-26 | Glaxo Group Ltd | Composition |
GB0326632D0 (en) | 2003-11-14 | 2003-12-17 | Jagotec Ag | Dry powder formulations |
KR20050056622A (ko) | 2003-12-10 | 2005-06-16 | 주식회사 대우일렉트로닉스 | 플레쉬롬 다운로드 장치 |
WO2005067898A2 (en) | 2004-01-07 | 2005-07-28 | Nektar Therapeutics | Improved sustained release compositions for pulmonary administration of insulin |
EP1713441A2 (en) | 2004-02-12 | 2006-10-25 | Nektar Therapeutics | Interleukin-13 antagonist powders, spray-dried particles, and methods |
US20050207983A1 (en) | 2004-03-05 | 2005-09-22 | Pulmatrix, Inc. | Formulations decreasing particle exhalation |
SE528121C2 (sv) | 2004-03-29 | 2006-09-05 | Mederio Ag | Preparering av torrpulver för på förhand uppmätt DPI |
CA2602596A1 (en) | 2004-03-30 | 2005-10-13 | Malcolm King | Compositions and methods for improved mucus function |
EP1734962A4 (en) | 2004-03-30 | 2010-07-14 | Painceptor Pharma Corp | COMPOSITIONS AND METHOD FOR MODULATING CONTROLLED ION CHANNELS |
US20050281740A1 (en) | 2004-06-16 | 2005-12-22 | Glen Gong | Imaging damaged lung tissue |
US7629385B2 (en) | 2004-06-29 | 2009-12-08 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Sphingolipid-derived pharmaceutical compositions |
DE102004031863B3 (de) | 2004-07-01 | 2006-03-09 | Airbus Deutschland Gmbh | Vorrichtung zur Fixierung von insbesondere flächenhaften Werkstücken mit einer Anlagefläche |
JP2008507585A (ja) | 2004-07-26 | 2008-03-13 | コセリックス インク | 微粒子製剤を用いて吸入したイロプロストによる肺高血圧症の治療 |
JP2008512475A (ja) | 2004-09-07 | 2008-04-24 | スミスクライン・ビーチャム・コーポレイション | アゴニストによるtrpv4チャネル受容体の活性化方法 |
US20060073173A1 (en) | 2004-10-04 | 2006-04-06 | Maria Banach | Large-scale manufacturing process for the production of pharmaceutical compositions |
GB0425758D0 (en) | 2004-11-23 | 2004-12-22 | Vectura Ltd | Preparation of pharmaceutical compositions |
US8627821B2 (en) | 2005-01-10 | 2014-01-14 | Pulmatrix, Inc. | Method and device for decreasing contamination |
WO2006084131A2 (en) | 2005-02-01 | 2006-08-10 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Furin inhibitors and alpha-defensins for the treatment or prevention of papillomavirus infection |
EP2463551B1 (en) | 2005-02-10 | 2015-04-08 | BorgWarner Inc. | Dual clutch transmission |
WO2006102438A2 (en) | 2005-03-23 | 2006-09-28 | Ihc Intellectual Asset Management, Llc | Methods and compositions for irrigation of mucosal tissues |
US20060229366A1 (en) | 2005-04-07 | 2006-10-12 | Lifschitz Carlos H | Method for preventing or treating respiratory infections in infants |
AU2006244478B2 (en) | 2005-05-05 | 2012-09-13 | Pulmatrix Inc. | Ultrasonic aerosol generator |
US7838532B2 (en) | 2005-05-18 | 2010-11-23 | Mpex Pharmaceuticals, Inc. | Aerosolized fluoroquinolones and uses thereof |
CA2900093C (en) | 2005-05-18 | 2018-11-13 | Mpex Pharmaceuticals, Inc. | Aerosolized fluoroquinolones and uses thereof |
EA016072B1 (ru) * | 2005-05-18 | 2012-01-30 | Палметрикс Инк. | Применение состава соли кальция для изменения биофизических свойств слизистой оболочки |
GB0520794D0 (en) | 2005-10-12 | 2005-11-23 | Innovata Biomed Ltd | Inhaler |
ITMI20051999A1 (it) * | 2005-10-21 | 2007-04-22 | Eratech S R L | Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita' |
EP1952160B1 (en) | 2005-10-31 | 2011-04-06 | Janssen Pharmaceutica NV | Methods for identifying modulators of trpv2 |
GB0523576D0 (en) | 2005-11-18 | 2005-12-28 | Theradeas Ltd | Drug composition and its use in therapy |
US20070202051A1 (en) | 2006-02-10 | 2007-08-30 | Pari Gmbh | Aerosols for sinunasal drug delivery |
US8026233B2 (en) | 2006-03-29 | 2011-09-27 | Array Biopharma Inc. | P38 inhibitors and methods of use thereof |
WO2008025560A1 (en) | 2006-09-01 | 2008-03-06 | Pari Pharma Gmbh | Methods for taste masking of nebulised compositions for nasal and pulmonary inhalation therapy |
US20080063722A1 (en) | 2006-09-08 | 2008-03-13 | Advanced Inhalation Research, Inc. | Composition of a Spray-Dried Powder for Pulmonary Delivery of a Long Acting Neuraminidase Inhibitor (LANI) |
EP2101748B9 (en) | 2006-11-29 | 2015-02-25 | Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. | Use of incensole and derivatives thereof for neuroprotection and for the treatment of depression and anxiety |
US8501255B2 (en) | 2006-12-14 | 2013-08-06 | Purac Biochem B.V. | Particulate composition comprising calcium lactate and calcium citrate microparticles |
GB0625322D0 (en) | 2006-12-19 | 2007-01-24 | Pharmakodex Ltd | Pharmaceutical compositions |
EP2011495A1 (en) | 2007-07-03 | 2009-01-07 | Sygnis Bioscience GmbH & Co. KG | Use of piperine and derivatives thereof for the therapy of neurological conditions |
WO2009037503A2 (en) | 2007-09-18 | 2009-03-26 | Astrazeneca Ab | New combination - 012 for the treatment of respiratory diseases |
GB0719518D0 (en) | 2007-10-05 | 2007-11-14 | Therapeutics Ltd E | Therapy |
EP2050437A1 (en) * | 2007-10-15 | 2009-04-22 | Laboratoires SMB | Improved pharmaceutical dry powder compositions for inhalation. |
EP2229364B1 (en) | 2007-12-05 | 2015-02-25 | Janssen Pharmaceutica, N.V. | Dibenzoazepine and dibenzooxazepine trpa1 agonists |
EP2080508A1 (en) * | 2008-01-15 | 2009-07-22 | CHIESI FARMACEUTICI S.p.A. | Dry powder formulation comprising an anticholinergic drug |
NO2252275T3 (ru) | 2008-02-13 | 2018-04-28 | ||
EP2098219A1 (en) | 2008-03-05 | 2009-09-09 | PARI Pharma GmbH | Macrolide compositions having improved taste and stability |
US8119647B2 (en) | 2008-04-23 | 2012-02-21 | Glenmark Pharmaceuticals S.A. | Fused pyrimidineone compounds as TRPV3 modulators |
MX2010012452A (es) | 2008-05-15 | 2011-03-15 | Novartis Ag Star | Suministro pulmonar de una fluoro-quinolona. |
EP2323640A2 (en) | 2008-08-04 | 2011-05-25 | Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. | Methods and compositions for treating neuronal damage and modulating transient receptor potential channels |
GB0818476D0 (en) | 2008-10-09 | 2008-11-12 | Vectura Delivery Device Ltd | Inhaler |
AU2010229721A1 (en) | 2009-03-26 | 2011-10-06 | Pulmatrix, Inc. | Methods for treating and preventing pneumonia and ventilator-associated tracheobronchitis |
WO2010111650A2 (en) | 2009-03-26 | 2010-09-30 | Pulmatrix, Inc. | Calcium citrate and calcium lactate formulations for alteration of biophysical properties of mucosal lining |
KR20120002981A (ko) | 2009-03-26 | 2012-01-09 | 풀매트릭스 인코퍼레이티드 | 호흡기 감염 치료를 위한 약제 제형 및 방법 |
WO2010111680A2 (en) * | 2009-03-26 | 2010-09-30 | Pulmatrix, Inc. | Dry powder formulations and methods for treating pulmonary diseases |
EP2410984A2 (en) | 2009-03-26 | 2012-02-01 | Pulmatrix, Inc. | Anti-influenza formulations and methods |
US20120172429A1 (en) | 2009-07-10 | 2012-07-05 | Woolf Clifford J | Permanently charged sodium and calcium channel blockers as anti- inflammatory agents |
GB0918450D0 (en) | 2009-10-21 | 2009-12-09 | Innovata Ltd | Composition |
WO2012030664A1 (en) | 2010-08-30 | 2012-03-08 | Pulmatrix, Inc. | Dry powder formulations and methods for treating pulmonary diseases |
WO2012030645A1 (en) | 2010-08-30 | 2012-03-08 | Pulmatrix, Inc. | Respirably dry powder comprising calcium lactate, sodium chloride and leucine |
IL286573B (en) * | 2010-09-29 | 2022-08-01 | Pulmatrix Operating Co Inc | Monovalent metallic cation dry powders for inhalation |
PT106094A (pt) | 2012-01-13 | 2013-07-15 | Hovione Farmaciencia S A | Administração por inalação de formulações com dose elevada |
US9216527B2 (en) | 2012-02-09 | 2015-12-22 | G & W Electric Company | Solid-dielectric switch including a molded viewing window |
WO2013130767A1 (en) * | 2012-02-29 | 2013-09-06 | Pulmatrix, Inc. | Inhalable dry powders |
CA3039485A1 (en) * | 2016-10-14 | 2018-04-19 | Pulmatrix Operating Company, Inc. | Antifungal dry powders |
-
2011
- 2011-09-29 IL IL286573A patent/IL286573B/en unknown
- 2011-09-29 US US13/876,312 patent/US9642798B2/en active Active
- 2011-09-29 CA CA2812414A patent/CA2812414C/en active Active
- 2011-09-29 CN CN201710140007.7A patent/CN107096014B/zh active Active
- 2011-09-29 AU AU2011308865A patent/AU2011308865B2/en active Active
- 2011-09-29 RU RU2017144619A patent/RU2017144619A/ru not_active Application Discontinuation
- 2011-09-29 WO PCT/US2011/053829 patent/WO2012044736A1/en active Application Filing
- 2011-09-29 RU RU2013118453A patent/RU2640921C2/ru active
- 2011-09-29 JP JP2013531826A patent/JP5877204B2/ja active Active
- 2011-09-29 MX MX2013003478A patent/MX354828B/es active IP Right Grant
- 2011-09-29 EP EP11770941.0A patent/EP2621484A1/en not_active Withdrawn
- 2011-09-29 KR KR1020187031481A patent/KR20180122475A/ko active Search and Examination
- 2011-09-29 CN CN201180057314.XA patent/CN103228273B/zh active Active
- 2011-09-29 EP EP21207551.9A patent/EP4008326A1/en active Pending
- 2011-09-29 BR BR112013007304-7A patent/BR112013007304B1/pt active IP Right Grant
- 2011-09-29 KR KR1020137010157A patent/KR101915241B1/ko active IP Right Grant
- 2011-09-29 CA CA3086367A patent/CA3086367A1/en active Pending
-
2013
- 2013-03-21 IL IL225398A patent/IL225398A/en active IP Right Grant
-
2015
- 2015-03-24 US US14/666,959 patent/US20150231066A1/en not_active Abandoned
-
2016
- 2016-01-25 JP JP2016011411A patent/JP6186458B2/ja active Active
- 2016-09-27 US US15/277,062 patent/US10376465B2/en active Active
- 2016-12-05 AU AU2016269398A patent/AU2016269398B2/en active Active
-
2017
- 2017-07-31 JP JP2017148309A patent/JP6392422B2/ja active Active
- 2017-12-17 IL IL256360A patent/IL256360B/en active IP Right Grant
-
2019
- 2019-06-28 US US16/456,990 patent/US20190388342A1/en not_active Abandoned
-
2020
- 2020-01-12 IL IL271976A patent/IL271976A/en unknown
- 2020-12-28 US US17/134,827 patent/US11173115B2/en active Active
-
2023
- 2023-08-23 US US18/454,289 patent/US20240156728A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2013118453A (ru) | Катионы одновалентных металлов сухих порошков для ингаляций | |
JP2013540123A5 (ru) | ||
RU2015146871A (ru) | Сухие порошки с тиотропием | |
JP2019534270A5 (ru) | ||
US9539211B2 (en) | Ultra low density pulmonary powders | |
JP2016512494A5 (ru) | ||
US11285107B2 (en) | Process for manufacturing porous silica particles loaded with at least one bioactive compound adapted for lung, nasal, sublingual, and/or pharyngeal delivery | |
RU2019114112A (ru) | Противогрибковые сухие порошки | |
JP5705112B2 (ja) | ドライパウダー吸入エアロゾル用の大径キャリア粒子を含む製剤 | |
KR20110120283A (ko) | 흡입용 약학적 조성물 | |
Pomázi et al. | Effect of polymers for aerolization properties of mannitol-based microcomposites containing meloxicam | |
JP2012518663A (ja) | 4−{(1r)−2−[(6−{2−[(2,6−ジクロロベンジル)オキシ]エトキシ}ヘキシル)アミノ]−1−ヒドロキシエチル}−2−(ヒドロキシメチル)フェノールを含む医薬製剤 | |
WO2011121425A1 (en) | Pharmaceutical powder composition for inhalation | |
RU2018112077A (ru) | Направленная доставка высушенных распылением композиций в легкие | |
Carvalho et al. | Dry powder inhalation for pulmonary delivery: recent advances and continuing challenges | |
JP2023521396A (ja) | ペラミビル乾燥粉末吸入剤及びその調製方法 | |
WO2012051050A1 (en) | Method for treating cystic fibrosis with inhaled denufosol | |
CN105012278B (zh) | 一种干粉吸入粉雾剂载体蔗糖及其制备方法 | |
JPWO2019204583A5 (ru) | ||
WO2022122012A1 (zh) | 用于肺部递送的药物组合物 | |
JP7304835B2 (ja) | 呼吸器系医薬品粉末及びその製造方法 | |
JP2017530988A5 (ru) | ||
RU2022101759A (ru) | Катионы одновалентных металлов сухих порошков для ингаляций | |
Parker et al. | Performance of the Micro device with different inspiratory flow rates | |
Ong | The aerosol performance and physico-chemical properties of co-milled dry powder formulations for high dose delivery |